NCT04588922 2026-03-16
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Phase 1/2 Recruiting
Sellas Life Sciences Group
Kura Oncology, Inc.
University of Alabama at Birmingham
Dana-Farber Cancer Institute
CellCentric Ltd.
M.D. Anderson Cancer Center
AbbVie
First Affiliated Hospital of Zhejiang University